Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 · New England Journal of Medicine · 4,750 citations
https://doi.org/10.1056/nejmoa060655
C
Christine Chevreau
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
494
Papers
28.0K
Citations
72
h-index
228
i10-index
Christine Chevreau is an academic researcher from Institut Claudius Regaud. The author has contributed to research in topics: Sarcoma Diagnosis and Treatment & Renal cell carcinoma treatment & Vascular Tumors and Angiosarcomas. The author has an h-index of 72, co-authored 420 publications.
ORCID: 0000-0001-9866-913XPapers by this author
worksNivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
2020 · Cancer · 331 citations
https://doi.org/10.1002/cncr.33033
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)
2011 · Annals of Oncology · 159 citations
https://doi.org/10.1093/annonc/mdr051
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
2024 · New England Journal of Medicine · 69 citations
https://doi.org/10.1056/nejmoa2403394
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
2015 · BMC Cancer · 47 citations
https://doi.org/10.1186/s12885-015-1697-8
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
2011 · British Journal of Cancer · 43 citations
https://doi.org/10.1038/bjc.2011.257
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat